Intensity Therapeutics

Historical price data

Intensity Therapeutics is pioneering a 'treat locally, act globally' approach to cancer therapy. Its core DfuseRx platform uses novel penetration enhancers to disperse cytotoxic drugs throughout injected tumors, inducing immunogenic cell death and triggering a CD4+/CD8+ T-cell response against both local and distant metastases. The company is advancing its lead asset, INT230-6, through multiple mid-to-late-stage trials in challenging solid tumors, with a strategic focus on neoadjuvant and metastatic settings to improve survival and prevent recurrence.

DfuseRx℠ is a proprietary penetration enhancer platform that enables intratumoral injection of cytotoxic agents, promoting dispersion throughout the tumor and inducing immunogenic cell death to activate a systemic anti-cancer immune response.

2 drugs in pipeline, 1 in Phase 3

Total raised: $25M

Intensity competes with other intratumoral therapy developers (e.g., oncolytic viruses, electroporation-based therapies) and large pharma with systemic immunotherapies. Its differentiation is the DfuseRx platform's ability to use established cytotoxics to achieve both local tumor kill and systemic immune activation, potentially offering a novel mechanism with a familiar safety profile.